Arexis AB
Acquired by Biovitrum (Sweden)
August 2005
Business:
Arexis AB, founded by experienced scientists in 1999, is a drug discovery and development company focusing on metabolic and inflammatory diseases. The Company is biology-driven with proprietary technology and a strong focus on product development. Arexis uses forward genetics for a high-resolution molecular dissection of causative disease mechanisms. This research strategy is generating a new clinical programme every year and continues to yield novel and proprietary drug targets, key to a more effective development of novel therapies.